Merck buys a fledgling neurodegenerative biotech spawned by an old GSK discovery alliance. What’s up with that?
Avalon Ventures chief Jay Lichter has a well-known yen for drug development programs picked up in academia. And what he found in Haoxing Xu’s lab at the University of Michigan pricked his interest enough to launch one of his umbrella biotechs in San Diego.
Xu’s work laid the foundation for Avalon to launch Calporta, which has been working on finding small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for lysosomal storage disorders. And that pathway, they believe, points to new approaches on major market neurodegenerative diseases like Parkinson’s, ALS and Alzheimer’s.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,500+ biopharma pros reading Endpoints daily — and it's free.